Sildenafil Cream, 3.6% has the Potential to Be the First FDA-Approved Product for FSAD SAN DIEGO, Dec. 11, 2019 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a...
BXCL701 may improve patient response when combined with checkpoint inhibitors or re-sensitize patients who have failed checkpoint therapy NEW HAVEN, Conn., Dec. 11, 2019 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a...
INDIANAPOLIS, Dec. 11, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the opening of the LIBRETTO-431 clinical trial [NCT04194944] for selpercatinib, also known as LOXO-292, for treatment-naïve RET fusion-positive non-small cell lung...
Tonix Pharmaceuticals, Inc. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first patient was enrolled in the Phase 3 RELIEF study (TNX-CY-F304). RELIEF is a potential pivotal study of TNX-102 SL*...
The RECOVER™ study is assessing real-world, patient-centered outcomes including abstinence from illicit opioids and life changes, such as improved health, employment status and connection to community following treatment with SUBLOCADE™ (Buprenorphine...
Email
Text